Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, October 10, 2026

Back to today

From X

@KEDM_COM 2 clicks

KEDM.com on X

Qiagen $QGEN has had a new CEO (Jonathan Pratt) since Sept. 1. Let's see if he can bring some action. The company also recently confirmed it continues to evaluate strategic alternatives, with Goldman Sachs involved. There have been reports of takeover interest for a long time, with past reports linking Qiagen to Thermo Fisher, bioMérieux, and Bio-Rad. Qiagen is an interesting target given its leadership in nucleic acid prep, strong consumables-driven revenue, and growth areas like TB testing and digital PCR. The portfolio would fit well with major industry consolidators.
@StableBread 2 clicks

Fajasy on X

“Tens of billions of new opportunity” is how BWX Technologies $BWXT CEO Rex Geveden describes uranium enrichment, the middle of the nuclear fuel chain. After naval reactors, $BWXT’s other big government business is uranium, which it calls special materials. It covers processing, downblending (diluting Cold War-era high-enriched uranium into lower-enriched fuel), and now enrichment for defense use. $BWXT says revenue grew from ~$285M in 2023 to ~$550M in 2026 guidance, 24%/year, and expects high-single to low-double-digit growth from there to 2030. Geveden named its two largest growth programs on the August 3 call, high-purity depleted uranium (HPDU) and defense fuels enrichment. $BWXT’s release on its purchase of Aerojet Ordnance Tennessee (A.O.T.) from L3Harris $LHX calls the unit the “sole provider of depleted uranium to the U.S. government.” Nine months after the purchase closed, $BWXT won a $1.6B, 10-year contract to produce up to 300 metric tons/year of HPDU at A.O.T.’s Jonesborough, Tennessee site. HPDU is depleted uranium metal refined to the purity the National Nuclear Security Administration (NNSA), the Department of Energy (DOE) agency running the nuclear weapons complex, needs at its Y-12 plant to maintain the deterrent. Construction starts in late 2026, per $BWXT’s Investor Day on September 29, 2026. For defense fuels, the military needs unobligated uranium, meaning uranium free of the peaceful-use pledges attached to foreign-supplied material. An August 2026 report from the Government Accountability Office (GAO), Congress’s audit arm, says the last U.S. plant able to enrich unobligated material, the Paducah plant in Kentucky, stopped in 2013. In September 2025, NNSA awarded $BWXT a sole-source contract valued at $1.5B to license, build, and run a pilot enrichment plant at Erwin, Tennessee, per the same report. $BWXT built a centrifuge manufacturing facility in Oak Ridge in seven months, plans to test its first prototype centrifuge by the end of 2026, and expects to file the Erwin license application in Q1 2027, with the plant running ~2035. Enrichment sits in the middle of the fuel chain, between uranium producers like Energy Fuels $UUUU and fuel plants like Erwin. The Investor Day deck says what’s “required to meet defense fuel needs through 2052” is $36.8B or more, citing the GAO and $BWXT’s own estimates. NNSA projects enough high-enriched uranium for naval propulsion “until the 2050s,” and enough unobligated low-enriched uranium for tritium (a hydrogen isotope used in nuclear warheads) through the early 2040s, per the same GAO report. Still, $BWXT earns revenue while it develops, licenses, and builds the plant, which is why the enrichment program drove most of the government segment’s Q2 2026 revenue growth.

Investor Letters

All letters

Namib Minerals: Research Note

Namib Minerals posted H1 adjusted EBITDA of $19.0 million, up 76%, as higher gold prices offset lower production.

NAMM $62M
Atrium Research - Equity Research

Golar LNG q2’26 Operational Update

Golar LNG ordered a $2.45 billion fourth FLNG vessel, targeting 3.5MTPA of capacity and $400 million in annual EBITDA under a 20-year…

GLNG $4.9B
Monte Independent Investment Research

What I’ve Been Up To

Cogent Communications and AI data-center bottlenecks feature in a newsletter update on recruiting, financial media and conference takeaways.

CCOI $515M
Stock Thoughts 1 click
BNTC · long

Benitec Biopharma INC

Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.

BNTC $314M
Value Investors Club

Solid Power Still Has Promise

Solid Power reported a $0.11 Q2 loss and $419.3 million of cash, with its electrolyte pilot line and BMW and SK On validation central to…

SLDP $528M
Quad 7 Capital 2 clicks

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 45 of 216

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.